Floatz logo

Evomela

Chordoma

Masonic Cancer Center, University of MinnesotaPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Chordoma cohort.

Asset / SponsorPhaseRating
Nivolumab
Sarcoma Oncology Research Center, LLC
Phase 2B
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Nab-Rapamycin
Sarcoma Oncology Research Center, LLC
Phase 1/2CCC
FLUDEOXYGLUCOSE
National Cancer Institute (NCI)
Phase 1/2CCC
Atezolizumab
National Cancer Institute (NCI)
Phase 1/2CCC

View all 13 →

Same molecule, other indications

Evomela is also rated in:

diffuse large B-cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
76 / 100
View asset →
myeloproliferative neoplasmDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →